Skip to main content
Equibles
AXSM logo

AXSM · Axsome Therapeutics, Inc. · Metrics

Track AXSM — free

Use AXSM with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research AXSM.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$155.81 -1.33 (-0.85%) At close · Oct 19
Russell 1000 member Rebalance outlook locked
Market Cap
$8.14B
Shares
52.38M
Volume · Oct 19 781.57K Avg daily vol (3M) 728.31K

AXSM metrics

76 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$155.81
Market cap
$8.14B

Price action

20 metrics
Price change (1W)
-6.7%
Price change (30D)
-23.5%
Price change (3M)
-31.7%
Price change (6M)
-16.9%
Price change (YTD)
-14.0%
Price change (1Y)
+25.7%
Trailing year
Price change (5Y)
+291.9%
52-week high
$255.17
52-week low
$125.00
Change from 52-week high
-38.4%
Change from 52-week low
+25.7%
Annualized volatility
44.0%
Annualized volatility (3M)
40.4%
Beta
0.6
RSI (14D)
23.9
Price vs SMA 50
-20.6%
Price vs SMA 200
-21.7%
Avg volume (3M)
729,801
Relative volume
1.2
Average dollar volume
$147.47M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
52.38M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
10.4×
reciprocal yield 9.6%
EV / EBITDA
—
EV / EBIT
—
P / sales
10.6×
reciprocal yield 9.4%
P / book
98.8
reciprocal yield 1.0%
FCF yield
-0.9%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-2.3%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
13.5×
reciprocal yield 7.4%
EV / revenue historical average (5Y)
13.8×
reciprocal yield 7.3%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
2026-11-02
Last earnings
2026-08-10

Profitability

9 metrics
Gross margin
—
Operating margin
-24.0%
Trailing 12 months
Net margin
-24.7%
Gross profit (TTM)
—
Operating profit (TTM)
−$186.07M
Net income (TTM)
−$191.64M
Trailing 12 months
Diluted EPS (TTM)
$-3.74
FCF margin
-9.3%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$15.24
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-3.65
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-3.76
Operating cash flow per diluted share (TTM)
$-1.39
Free cash flow per diluted share (TTM)
$-1.40
Capital expenditures per diluted share (TTM)
$0.01
R&D per diluted share (TTM)
$3.69
Stock compensation per diluted share (TTM)
$1.89
Book value per share
$1.74

Growth

11 metrics
Revenue growth YoY
+45.5%
Year over year
Net income growth YoY
—
Revenue (TTM)
$776.57M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+4.8%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-230.1%
Return on assets
-25.2%
Debt / equity
2.3
Current ratio
1.4
EBITDA (TTM)
—
Free cash flow (TTM)
−$71.96M
Quick ratio
1.3
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$131.89M
Latest balance sheet
Cash & equivalents
$319.85M
Total assets
$761.45M
Total debt
$187.96M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$71.26M
Capital expenditures (TTM)
$700,000
R&D (TTM)
$187.86M
SG&A (TTM)
$712.66M
Stock compensation (TTM)
$96.42M
R&D / revenue
24.2%
Stock compensation / revenue
12.4%

Ownership (13F)

3 metrics
13F filers
512
13F filer change QoQ
+96
Institutional ownership
76.5%

Short interest

3 metrics
Short interest
6.3%
Latest settlement · 4.4 days to cover
Days to cover
4.4d
Short-squeeze score
64 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$12.62M
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1579428 CUSIP 05464T104 13F (30d) 41 filings 37 filers Visit website Investor relations